Bayforest Capital Ltd Purchases New Stake in Novavax, Inc. $NVAX

Bayforest Capital Ltd purchased a new stake in shares of Novavax, Inc. (NASDAQ:NVAX) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 62,983 shares of the biopharmaceutical company’s stock, valued at approximately $404,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sanofi bought a new stake in Novavax during the 4th quarter valued at $55,319,000. Park West Asset Management LLC bought a new stake in Novavax during the 1st quarter valued at $16,210,000. Northern Trust Corp raised its holdings in Novavax by 6.1% during the 4th quarter. Northern Trust Corp now owns 1,451,715 shares of the biopharmaceutical company’s stock valued at $11,672,000 after buying an additional 83,503 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Novavax by 289.0% during the 4th quarter. BNP Paribas Financial Markets now owns 556,832 shares of the biopharmaceutical company’s stock valued at $4,477,000 after buying an additional 413,676 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Novavax during the 1st quarter valued at $3,280,000. 53.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of Novavax in a research report on Thursday, August 28th. They set a “buy” rating and a $10.00 price objective on the stock. B. Riley reissued a “buy” rating on shares of Novavax in a research report on Monday, May 19th. Citigroup assumed coverage on shares of Novavax in a research report on Tuesday, June 17th. They set a “sell” rating and a $6.00 price objective on the stock. Finally, Bank of America reissued an “underperform” rating and set a $7.00 price objective (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $14.29.

Novavax Price Performance

NASDAQ:NVAX opened at $7.96 on Thursday. The firm’s 50-day moving average price is $7.60 and its 200-day moving average price is $7.15. The company has a market capitalization of $1.29 billion, a PE ratio of 3.49, a P/E/G ratio of 0.10 and a beta of 2.68. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. Novavax, Inc. has a 1-year low of $5.01 and a 1-year high of $15.22.

Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. The firm had revenue of $239.24 million for the quarter, compared to the consensus estimate of $149.19 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The company’s revenue was down 42.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.99 EPS. On average, equities analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.